GlassScriptPhysician profile
George W Diggs
NPI 1699700880
$7,012.73
in general payments reported to CMS, 2019-2025
19 companies · $2,087 in 2025
The $2,087 reported for 2025 was more than what 90% of Addiction Psychiatry providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $93.38 · 2021: $492 · 2022: $628 · 2023: $1,752 · 2024: $1,609 · 2025: $2,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,225 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,225.44 |
| Education | $222.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,358.58 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $1,183.95 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $1,157.18 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $912.87 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $561.95 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $557.47 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $398.34 | 2020-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $255.82 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $235.50 | 2020-2025 | Fanapt |
| Indivior INC. | $95.51 | 2022-2025 | Sublocade |
| Lundbeck LLC | $51.67 | 2022-2023 | Rexulti |
| Philips North America LLC | $45.46 | 2019 | |
| Braeburn INC. | $42.30 | 2025 | Brixadi |
| Allergan, INC. | $40.64 | 2019-2020 | |
| Axsome Therapeutics, INC. | $35.72 | 2024-2025 | Auvelity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $26.33 | 2019 | |
| Noven Therapeutics, LLC | $19.77 | 2023 | Secuado, Xelstrym |
| Luye Pharma (USA) LTD. | $16.99 | 2025 | Erzofri Extended-Release |
| Bioxcel Therapeutics, INC. | $16.68 | 2024 | Igalmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Diggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.